NCT05206071

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Hebei Senlang Biotechnology Inc., Ltd. · Industry
• Sex: All
• Age: 3 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.

Detailed description

SL19+22 injection is a CAR-T product independently developed by Senlang that targets both CD19 and CD22. Based on the traditional CAR T treatment regimen, the CAR structure was designed, and the activation mode of T cells was changed by using cytokine combination amplification and improved transfection technology. The Main research objectives: To evaluate the safety and efficacy of SL19+22 in patients with recurrent or refractory non-Hodgkin's lymphoma The Secondary research objectives: To investigate the cytokinetic characteristics of SL19+22 in patients with recurrent or refractory non-Hodgkin's lymphoma.

Conditions

• Non-hodgkin's Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CD19+22 CAR-T cells	Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;

Timeline

• Start date: 2021-05-01
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2022-01-25
• Last updated: 2022-01-25

Locations

1 site across 1 country: China